Article,
The challenges for implementing Good Clinical Practices in the bioanalytical laboratory: a discussion paper from the European Bioanalysis Forum
Affiliations
- [1] European Bioanalysis Forum, Havenlaan 86c b204, Brussels, 1000, Belgium [NORA names: Belgium; Europe, EU; OECD];
- [2] Quality & Compliance, Comac Medical, Sofia, 1404, Bulgaria [NORA names: Bulgaria; Europe, EU];
- [3] AstraZeneca (Sweden) [NORA names: Sweden; Europe, EU; Nordic; OECD];
- [4] Roche Innovation Center Welwyn, Roche Pharma Research & Early Development, Welwyn Garden City, Hertfordshire, AL7 1TW, UK [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [5] J&J Innovative Medicine, Quality Assurance, Beerse, 2340, Belgium [NORA names: Belgium; Europe, EU; OECD];
(... more)
Abstract
This manuscript reports back from the discussion in the European Bioanalysis Forum community on the challenges observed when implementing Good Clinical Practices in the bioanalytical laboratory. It is not intended to challenge any regulatory requirements but to open a discussion on where the bioanalytical community sees ambiguities on implementing Good Clinical Practices or areas where expectations are either felt not being owned by Bioanalysis or where Good Clinical Practices requirements are at risk of getting contaminated with requirements originating from Good Laboratory Practices. In addition to this, the discussions focused on three additional main challenges: the informed consent withdrawal, expedited reporting of unexpected results and the risk-based approach to quality management, The European Bioanalysis Forum community is continuing discussions, but already this manuscript should help to appreciate the challenges and to try and resolve them, involving all stakeholders.